Dr. Lal Path Labs Ltd. has informed the Exchange about acquisition of 100% stake in Shahbazkers Diagnostic Centre Private Limited ( SDCPL ) from its existing Shareholders. Post acquisition, SDCPL shall become a Wholly Owned Subsidiary of the Company.
LALPATHLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Dr. Lal PathLabs reported strong FY26 results with consolidated revenue of Rs 27,629 million (up 12% YoY) and profit after tax of Rs 5,098 million (up 4% YoY). The Board approved acquisition of 100% stake in Shahbazkers Diagnostic Centre Private Limited, making it a wholly-owned subsidiary. Additionally, the company will incorporate a new wholly-owned subsidiary in Dubai, UAE (Dr. Lal PathLabs FZCO). For shareholders, a final dividend of Rs 4 per share is recommended (total FY26 dividend: Rs 20.5 per share). Key director re-appointments include Executive Chairman Dr. Arvind Lal and Independent Director Rajit Mehta for 5-year terms. EPS for FY26 stands at Rs 30.24.
The acquisition of SDCPL expands Dr. Lal PathLabs' diagnostic network, while the Dubai subsidiary marks international expansion. Strong 12% revenue growth and total dividend of Rs 20.5 per share are positive signals for shareholders.